AUTHOR: Authored by Wendy Roberts, PR Director of Orca Communications Unlimited, LLC.
COMMENT BY BIOINFORMANT: Leading global players within cord blood industry frequently attain their industry dominance through industry collaborations. In the announcement below, released May 11, 2015, CariCord and ClinImmune Labs announce a major industry partnership that will study the survivability of umbilical cord blood stem cells under micro gravity (Micro-G) simulation.
CariCord, a private stem cell bank at the University of Colorado, is a FDA-licensed cord blood manufacturer that has processed nearly 9,000 cord blood units and released 700+ for transplantation across 150+ hospitals worldwide. While CariCord is not as substantial in size as other key players within the U.S. cord blood industry (most notably Cord Blood Registry, ViaCord, and Cryo-Cell, respectively) the company is positioning itself for increased visibility and growth through this strategic collaboration.
MC, E-P Therapeutics, Forever Identity and ClinImmune/Caricord collaborate on studies and testing of UCB Stem Cell survivability under Micro Gravity (Micro-G) simulation
May 12, 2015; Orca Communications Unlimited, LLC
In May 2015, the International Space Medicine Consortium (ISMC) will commence a study comparing the differentiation of Umbilical Cord Blood (UCB) stem cell survivability under “1G” and “Micro-G” conditions at its Micro-G laboratory in Connecticut. Micro-G simulates the condition aboard the International Space Station (ISS) and activities in Low Earth Orbit (LEO). The UCB stem cells to be used for the study will be furnished by the ClinImmune/Caricord bank at the University of Colorado.
The study will also apply the EPeptide developed by E-P Therapeutics under 1G and Micro-G conditions and compare the functionality of the neural differentiated stem cells to measure the E-Peptide action performance yield. The E-Peptide, a small protein, has been observed to cause primary neural cells to develop dendrites. This suggests enhanced maturation will occur with the addition of E-Peptide to UCB stem cells that are being stimulated for neural expression. The ClinImmune/Caricord team will also participate in the verification analysis post differentiation for neural therapeutic applications in 1G and Micro-G conditions. The results of this study are critical to the ISMC dedication to the improvement of space medicine and its unmet medical challenges.
ClinImmune/Caricord has one of the largest and highest quality stem cell repositories in the world, including a second generation inventory of FDA Licensed drug units, (with some of the highest TNC levels) that were produced as lifesaving drugs for global distribution, and a high quality private bank consumer inventory that is securely maintained at the ClinImmune University of Colorado Medical Center repository. They will also conduct research into new uses of newborn stem cells in conjunction with ISMC and other strategic partners. (www.Caricord.com) (www.clinlmmune.com )
EP Therapeutics has identified an E peptide that not only activates neuroblastoma cells to form dendrites, but also stimulates progenitor cells or quiescent cells of the pituitary gland to proliferate. This combined effect on neural and neuroendocrine cells creates the promise of helping umbilical cord stem cells to mature faster into islet cells. This will also be tested in micro g and g environments. Another interesting attribute of E peptide is its stimulation of fibroblasts. Fibroblasts are necessary in wound closure. The presence of E peptide in granulation tissue could help make wound closure faster. (www.eptherapeutics.com)
The ISMC study will be under the direction of Dr. Steven Diamond, ISMC President/COO and Dr. Thais Russomano, ISMC Senior Vice President and Chief Medical Officer. The study will support the ISMC investigative diagnostic and therapeutic protocols addressing Traumatic Brain Injury (TBI), Intracranial Pressure (ICP) in the Space Mission environment and further 1G research to study Deep Brain Stimulation (DBS) factors.
As a part of these Space Medicine activities, ISMC has negotiated an exclusive partnership with Forever Identity (www.foreveridentity.com) to develop a 3-D holographic persona and is researching its application in interactive robotics and cognitive intelligence. Forever has researched and developed an application specific empathy platform that ISMC is actively investigating for robotic clinical psychology and diagnostic space medicine protocols. . (www.ISMCinc.com).
Barry Ressler, ISMC Chairman and Chief Executive Officer expressed the importance of aligning IMSC’s internal scientific, medical, and Micro-G expertise with the collaborative partners disclosed in this release and ISMC’s plans to globally expand its network of space technology partners. ISMC is committed to connecting space exploration and humanity by pioneering space medicine technologies and applications. This commitment will position ISMC to support future U.S. and international human spaceflight missions and the emerging commercial space tourism industry.
Future Cord Blood Updates
If you enjoyed this post about the cord blood industry, sign up below. It may just give you a strategic edge over your competition.
BioInformant is the only research firm that has served the cord blood sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, Medical Ethics, CBS News, and the California Institute for Regenerative Medicine (CIRM).
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in cord blood industry data.
To learn more about trends and opportunities within the cord blood banking industry, view the “Complete 2015-16 Global Cord Blood Banking Industry Report” now.
DISCLAIMER: This press release includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2012 and beyond could differ materially from the Company’s current expectations. Forward-looking statements are identified by words such as “anticipates,” “projects,” “expects,” “plans,” “intends,” “believes,” “estimates,” “targets,” and other similar expressions that indicate trends and future events. Factors that could cause the Company’s results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company’s products and services, the frequency, magnitude and timing of paper and other raw-materialprice changes, general business and economic conditions beyond the Company’s control, timing of the completion and integration of acquisitions, the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment strategies, and the Company’s success in attracting and retaining key personnel. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information, since these statements may no longer be accurate or timely.